GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (FRA:ANW) » Definitions » Long-Term Capital Lease Obligation

Immuron (FRA:ANW) Long-Term Capital Lease Obligation : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Immuron Long-Term Capital Lease Obligation?

Immuron's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil.

Immuron's quarterly Long-Term Capital Lease Obligation declined from Dec. 2022 (€0.10 Mil) to Jun. 2023 (€0.09 Mil) and declined from Jun. 2023 (€0.09 Mil) to Dec. 2023 (€0.00 Mil).

Immuron's annual Long-Term Capital Lease Obligation increased from Jun. 2021 (€0.00 Mil) to Jun. 2022 (€0.12 Mil) but then declined from Jun. 2022 (€0.12 Mil) to Jun. 2023 (€0.09 Mil).


Immuron Long-Term Capital Lease Obligation Historical Data

The historical data trend for Immuron's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Long-Term Capital Lease Obligation Chart

Immuron Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only - 0.01 - 0.12 0.09

Immuron Semi-Annual Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.12 0.10 0.09 -

Immuron  (FRA:ANW) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Immuron Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Immuron's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Immuron (FRA:ANW) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (FRA:ANW) » Definitions » Long-Term Capital Lease Obligation
Traded in Other Exchanges
Address
Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (FRA:ANW) Headlines

No Headlines